Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus ustekinumab in adults with moderate to severe Crohn's disease after prior anti-TNF failure
CTR20211582Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab, ustekinumab in Crohn's disease, sponsored by AbbVie Inc.. Started Aug 2021; status: active.
02
Drugs
risankizumabustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20211582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211582.